文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向成纤维细胞激活蛋白的喹啉类诊疗一体化配体的开发

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
PubMed 文献 · J Nucl Med · 2018-04-06

本研究合成并表征了15种基于喹啉结构的FAP抑制剂,其中FAPI-04在人血清中稳定性好、对FAP亲和力高于CD26且体外排泄较慢,在荷瘤动物中SUV更高;2例转移性乳腺癌患者的68Ga-FAPI-04 PET/CT显示转移灶高摄取,经低剂量90Y-FAPI-04治疗后疼痛症状减轻。

要点

  • 15种合成FAP抑制剂中FAPI-04被确定为最有前景的临床示踪剂。
  • FAPI-04较FAPI-02在人血清中稳定性优异、对FAP亲和力更高且体外排泄更慢。
  • 2例转移性乳腺癌患者68Ga-FAPI-04 PET/CT示转移灶高摄取,90Y-FAPI-04治疗后疼痛减轻。

核心结论

  • FAPI-04是用于高含量活化成纤维细胞恶性肿瘤(如乳腺癌)诊断显像及可能的靶向治疗的有前景示踪剂。

研究设计与样本

  • 合成基于喹啉结构的FAP抑制剂,并在表达人及鼠FAP以及CD26的细胞中表征其结合、内化和外排。
  • 在荷瘤动物中通过生物分布实验和小动物PET确定临床前药代动力学。
  • 对2例转移性乳腺癌患者进行影像与治疗的验证性探索。

主要发现

  • 在15种合成的FAP抑制剂中,FAPI-04被确定为最有前景的临床用示踪剂。
  • 与已发表的配体FAPI-02相比,FAPI-04在人血清中稳定性优异、对FAP较CD26亲和力更高且体外排泄更慢。
  • 在体内,荷瘤动物中达到更高的SUV,使生物分布实验计算的曲线下面积更大。
  • 2例转移性乳腺癌患者的68Ga-FAPI-04 PET/CT显示转移灶高示踪剂摄取,经相当低剂量90Y-FAPI-04治疗后疼痛症状减轻。

关键数值与推荐

  • FAPI-04在人血清中稳定性优异、对FAP亲和力高于CD26且体外排泄较FAPI-02慢。
  • 荷瘤动物中FAPI-04的SUV高于FAPI-02,生物分布实验计算的曲线下面积更大。
  • 2例转移性乳腺癌患者68Ga-FAPI-04 PET/CT示转移灶高摄取,90Y-FAPI-04治疗剂量相当低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts and is involved in a variety of tumor-promoting activities such as matrix remodeling, angiogenesis, chemotherapy resistance, and immunosuppression. Because FAP shows low expression in most normal organs, it presents an interesting target for imaging and endoradiotherapy. In this investigation, FAP inhibitors (FAPIs) were modified and optimized for use as theranostic tracers. Methods: FAPIs based on a quinoline structure were synthesized and characterized with respect to binding, internalization, and efflux in cells expressing human and murine FAP as well as CD26. Preclinical pharmacokinetics were determined in tumor-bearing animals with biodistribution experiments and small-animal PET. Finally, a proof-of-concept approach toward imaging and therapy was chosen for 2 patients with metastasized breast cancer. Results: Of 15 synthesized FAPIs, FAPI-04 was identified as the most promising tracer for clinical application. Compared with the previously published ligand, FAPI-02, FAPI-04 showed excellent stability in human serum, higher affinity for FAP as opposed to CD26, and slower excretion in vitro. In vivo, a higher SUV was reached in tumor-bearing animals, leading to larger areas under the curve as calculated from biodistribution experiments. Finally, PET/CT scans with 68Ga-FAPI-04 in 2 patients with metastasized breast cancer revealed high tracer uptake in metastases and a reduction in pain symptoms after therapy with a considerably low dose of 90Y-FAPI-04. Conclusion: FAPI-04 represents a promising tracer for both diagnostic imaging and, possibly, targeted therapy of malignant tumors with a high content of activated fibroblasts, such as breast cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018. PMID: 29626119. doi:10.2967/jnumed.118.210443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。